Brief: Anixa Biosciences Gets FDA Approval Of Individual Patient IND For Its Ovarian Cancer Car-T Therapy
23/07/2024 13:26
July 23 (Reuters) - Anixa Biosciences Inc ANIX.O :
* ANIXA BIOSCIENCES ANNOUNCES FDA APPROVAL OF INDIVIDUAL
PATIENT
IND FOR ITS OVARIAN CANCER CAR-T THERAPY
Source text for Eikon: ID:nPn66pJYXa
Further company coverage: ANIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine